Evaluation and Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus Patients after Glucocorticoid Withdrawal (PRESS): An Open- Label, Multicentre, Non-Inferiority, Randomized Controlled Study in China

医学 内科学 随机对照试验 羟基氯喹 随机化 临床终点 糖皮质激素 系统性红斑狼疮 意向治疗分析 疾病 传染病(医学专业) 2019年冠状病毒病(COVID-19)
作者
Yunyun Fei,Lidan Zhao,Lijun Wu,Xiaoxia Zuo,Rongli Li,Jiaomei Cheng,Hui Luo,Xue Wu,Li Sun,Jingjing Xu,Yingxuan Zhu,Yang Wang,Chen Zhu,Xiaomei Li,Xiaofei Wang,Xuan Zhang,PRESS Study Team
标识
DOI:10.2139/ssrn.4691765
摘要

Background: Low dose glucocorticoid (GC) maintenance in stable systemic lupus erythematosus (SLE) is universally adopted to prevent disease relapse which is associated with increased accumulated disease damage. The relapse risk of glucocorticoid withdrawal in stable SLE patients and whether hydroxychloroquine (HCQ) can substitute for GC as maintenance are unclear.Methods: The PRESS trial is a multicentre, 33-week, open-label, three-arm, non-inferiority design, randomized controlled trial conducted in China. SLE patients without severe organ disfunction and with sustained stabilized disease for more than one year who were maintained on low-dose GC plus HCQ therapy, were screened for eligibility. Qualified patients were sequentially recruited and assigned to three groups. Drug-free Group: both GC and HCQ withdrawal management; HCQ Group: discontinued GC but maintained HCQ dosage; Dual Maintenance Group: both GC and HCQ continued without change. The primary endpoint was to compare the proportion of patients experiencing a flare as defined by the SELENA-­SLEDAI flare index (SFI) by week 33. Two parallel non-inferiority analysis were performed (Drug-free Group vs. Dual Maintenance Group and HCQ Group vs. Dual Maintenance Group) to explore the difference of relapse risk. This trial is registered with ClinicalTrials.gov, NCT 02842814.Findings: From November 3rd, 2016 through August 13th, 2021, 352 patients fulfilling the inclusion criteria were randomized, and a total of 333 participants who practically implemented the intervention according to the protocol after randomization were analysed. The average age was 37.35±10.34, and the gender ratio of F:M being 21.2:1. The flare rates in the three groups (Drug-free Group, HCQ Group, and Dual Maintenance Group) were 26.1%, 11.2% and 4.7%, respectively. Compared with Dual Maintenance Group, Drug-free Group failed to achieved non-inferiority significance in relapse rate (rate difference 21.4%; 95% CI 11.4%-31.4%; Pnon-inferiority=0.2381), whereas HCQ Group achieved noninferiority in the relapse rate as compared with Dual Maintenance Group (rate difference 6.5%; 95% CI 1.4%-14.4%; Pnon-inferiority=0.0336). HCQ Group also exhibited fewer flares than Drug-free Group (P=0.0059). The SLE damage index and adverse events were similar among all three groups.Interpretation: Over two-thirds of long-term stable and quiescent SLE patients could enjoy GC-free or even drug-free for at least 33 weeks when sustained remission had obtained over 1 year. HCQ maintenance may exert a protective role in preventing disease relapse after GC withdrawal. Keywords: relapse risk; systemic lupus erythematosus; glucocorticoid withdrawal; hydroxychloroquine maintenanceTrial Registration: This trial is registered with ClinicalTrials.gov, NCT 02842814.Funding: This study was supported by the National Natural Science Foundation of China (82230060, 81788101, 82271856, 82071840), the Key R&D plan of the Ministry of Science and Technology (2022YFC3602000), Chinese Academy of Medical Science Innovation Fund (CIFMS 2020-I2M-C & T-A-002, 2021-1-I2M-017, 2021-1-I2M-047), and the National High-Level Hospital Clinical Research Funding (2022-PUMCH-C-039, 2022-PUMCH-B-013, 2022-PUMCH-A-108, BJ-2022-116).Declaration of Interest: The authors declared no interests of conflicts.Ethical Approval: Five geographically representative tertiary rheumatology centres across China, including Peking Union Medical College Hospital (PUMCH) (Central), the First Affiliated Hospital of University of Science and Technology of China (East), People’s Hospital of Xinjiang Uygur Autonomous Region (West), Shengjing Hospital (North), and Xiangya Hospital (South), participated in this trial. Ethics approval for this study was obtained from the ethics committees of all five centres. Written informed consent was obtained from all participants.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李飞龙发布了新的文献求助10
1秒前
jinshui111完成签到,获得积分10
1秒前
1秒前
诺言deer完成签到 ,获得积分10
1秒前
jgz1215发布了新的文献求助10
2秒前
超级安阳完成签到 ,获得积分10
3秒前
科研通AI2S的应助被Feven7采纳,获得10
4秒前
CYT完成签到,获得积分10
6秒前
路lu完成签到,获得积分10
7秒前
外向板栗发布了新的文献求助10
8秒前
小蘑菇的应助被1024504036采纳,获得10
8秒前
英俊的铭的应助被1024504036采纳,获得10
8秒前
领导范儿的应助被1024504036采纳,获得10
8秒前
柔弱傲丝完成签到,获得积分10
8秒前
bkagyin的应助被1024504036采纳,获得10
8秒前
奥利奥扭不开怎么办完成签到,获得积分10
9秒前
情怀的应助被1024504036采纳,获得10
9秒前
科研通AI65的应助被1024504036采纳,获得10
9秒前
Owen的应助被1024504036采纳,获得10
9秒前
TheNeuron完成签到,获得积分10
9秒前
9秒前
眼睛大夏柳完成签到,获得积分10
10秒前
清i晨完成签到,获得积分10
11秒前
11秒前
12秒前
张伟的应助被sagitar采纳,获得50
12秒前
小二郎的应助被yyps采纳,获得10
12秒前
13秒前
13秒前
孤独白拍完成签到,获得积分10
13秒前
zworld完成签到 ,获得积分10
13秒前
13秒前
11完成签到,获得积分10
15秒前
孤独白拍发布了新的文献求助20
16秒前
李爱国的应助被科研通管家采纳,获得10
16秒前
SciGPT的应助被科研通管家采纳,获得10
17秒前
英姑的应助被科研通管家采纳,获得10
17秒前
Wenlia的应助被科研通管家采纳,获得10
17秒前
所所的应助被赖葡萄采纳,获得10
17秒前
再睡亿分钟完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552